In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors, and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market the formulation demands for antibody-drug conjugates (ADCs) are significant. Antibodies have historically been administered at relatively low concentrations through intravenous (IV) infusion due to their large size and the inability to formulate for oral delivery. Due to the high demands associated with IV infusion and the development of novel antibody targets and unique antibody conjugates more accessible routes of administration such as intramuscular (IM), and subcutaneous (SC) are being explored. This review will summarize various site-specific and non-site-specific antibody conjugation techniques in the context of antibody-drug conjugates (ADCs) and the demands of formulation for high concentration clinical implementation.
INTRODUCTION

ANTIBODY FORMULATION
After a clinical target has been determined and an antibody has been selected it is necessary to formulate the antibody therapeutic prior to clinical use. Antibody formulation is a complex optimization process utilizing unique pharmaceutical additives to address the varying demands of storage, freeze-thaw, and route of administration necessary for the clinical application. There has been an ever-growing trend to increase the concentration of antibodybased therapeutics for clinical applications making the formulation process more difficult. This is largely driven by the desire to decrease the volume of injection while still providing for the same dose of drug to be administered. The primary reason for this industry push is to enhance clinical outcomes and to allow for more flexible routes of administration.
Most antibody therapeutics are given systemically through an IV requiring a healthcare professional to first attain venous access and then set up the infusion. IV is an excellent route of drug administration for large volume drugs but the complications and difficulties that arise with venipuncture make IV less accessible than comparable intramuscular (IM) and subcutaneous (SC) injection modalities. It is important to note that there is a limit to the volume (< 1.5 mL) that can be injected SC which is why antibody formulations are being pushed toward the 100's of mg/mL concentrations to allow for smaller volumes while still being able to attain a therapeutically relevant delivery of the pharmaceutical agent.(6,7) IM and SC administration also provides for different release kinetics, bioavailability, and extended half-life in some instances that can allow the periods between drug administrations to potentially be extended. (8) With the development of antibodies for more chronic diseases having a subcutaneous injection route would allow for self-administration of a drug, similar to insulin, which would greatly increase accessibility. For these reasons it is not surprising that antibody formulation has been pushing the boundaries of concentration. To add to the complexity it is not simply sufficient to formulate an antibody at a very high stable concentration as the resulting formulation must also fall within physical parameter boundaries of viscosity. (9, 10) This is particularly important for auto-injectors but also plays a role in syringe based injection with various syringe geometries and loading assemblies helping to improve tolerance of high viscosity formulations. At ultra-high viscosities it is nearly impossible to force the high antibody concentration formulation through a small bore needle making administration, regardless of stability, unreasonable. (11, 12) Antibody formulation is best addressed early and often through the entirety of the antibody development lifecycle with the final antibody formulation for clinical use being finalized as early as possible in the development process. It is a mistake to not consider the demands of formulation upon selection of a lead compound early in development as not every antibody can be formulated in any way to achieve a specific outcome. Each unique delivery method (IV, IM, SC, auto-injector), unique molecular entity (antibody, protein, nanoparticle, small molecule), and unique target (cancer, non-cancer) require different formulation conditions to ensure that maximum stability and shelf-life can be attained. (13) (14) (15) The process of formulating an antibody therapeutic is complex requiring first an understanding of how the protein handles exposure to stressors such as: freeze/thaw, agitation, thermal stability, and pH/buffer response followed by the addition of excipients to mitigate undesirable protein instabilities. (16, 17) An excipient is any additive that is included in a formulation that is used to stabilize the formation that is not considered an active ingredient. Example excipients include: fillers, extenders, diluents, solvents, preservatives, absorption enhancers, and sustained-release matrices. There is a relatively short list of buffers and excipients that are currently FDA To address the high demands for stability and concentration and the limited number of approved stabilizing compounds a large amount of effort has been placed on the sequence of optimization steps used to produce the most stable final antibody formulation. An example of this is to first test a series of buffers and buffer concentrations and select for the most stable buffer composition. Following buffer selection excipients are then added sequentially, optimizing at each step, to selectively mitigate instabilities observed as concentration is increased modulating pH, ionic strength, surfactants, cryoprotectants, and other stabilizing agents working toward a final clinical formulation. There are a number of techniques utilized to determine the optimal formulation for each unique monoclonal antibody or ADC. Common characterization techniques that assess the antibody stability and activity following exposure to diverse stressed conditions include: size exclusion chromatography (SEC) to detect aggregate formation, ion-exchange chromatography (IEC) or isoelectric focusing to detect charge variants generated by chemical instability, capillary electrophoresis sodium dodecyl sulfate (CE-SDS) for detection of fragmentation, mass spectrometry, and potency assays for biological activity. (20, 21) Typical methodologies for assessing the antibody stability in its native formulation state include: molecular modeling to assess surface characteristics, dynamic light scattering (DLS) to assess self-association propensity and pH effects, isothermal chemical denaturation (ICD) to assess optimal buffer conditions, differential scanning calorimetry (DSC) to assess thermal stability, and particulate formation characterization. (22) There are a number of proprietary formulation platforms that automate some of the processing but it is important to note that the ultimate formulation determination does depend on the route of optimization as different routes infrequently result in the same final optimized formulation.
ANTIBODY CONJUGATION
While the capabilities of unconjugated, first-generation antibodies, are impressive there is a growing trend toward endowing the native antibody with unnatural capabilities (immuno-conjugates) to enhance therapeutic efficacy. This comes in the most common form as a treatment of cancer utilizing antibody-drug-conjugates (ADCs). ADC formulations possess conjugated cytotoxic drugs that have enhanced localized effects through targeted delivery utilizing the antibody to provide specificity and the cytotoxic payload as an active agent. There are several different methods (both site-specific and non-site-specific) to conjugate functional ligands to antibodies. Conjugation options for antibody modification can be split into three primary categories: naturally occurring sites of modification that exist in the native antibody structure (Natural), non-naturally occurring sites that can be added to the antibody backbone through genetic manipulation (Non-Natural), and unique (Specialty) antibody modification modalities that do not fall neatly in either the Natural or Non-Natural modification categories Minimizing the variability in DAR is important as higher heterogeneity can result in varied pharmacokinetics, reduced half-life, increased plasma clearance, increased toxicity, and will increase the difficulty to attain a stable clinical formulation.
Natural
Antibodies are relatively large ~150 kDa glycoproteins that have many naturally occurring sites for conjugation. There are chemistries for conjugating to many of the 20 canonical amino acids. (26, 27) Despite the numerous available chemistries, the most common site for conjugation to proteins in general is through the ε-amine lysine side chain (1). Due to the high abundance of lysine residues (>80 in the native antibody backbone), its positive charge, its relatively long extension into solution, and its readily accessible aqueous conjugation techniques it remains the most utilized technique despite not being site-specific. 
Non-Natural
There are two primary non-natural antibody modification techniques that require utilization of genetic engineering to either insert a non-natural amino acid (6) or place an engineered cysteine residue (7) 
ADC FORMULATION CHALLENGES
Unique challenges exist when formulating an ADC compared to a naked mAb. As detailed earlier, sample complexity plays a major role in making formulation of a non-site specific ADC exceptionally difficult due to the diverse array of post conjugation species. In addition, the drugs that are attached to ADCs and the linker by which the drug is attached also instill added complexity to formulate an ADC. The means by which the drugs are attached to the antibody is also a unique hurdle that needs special attention when considering formulation of an ADC compared to a naked mAb.
Linkers vary in chemical composition providing the ADC with differing cleavable capabilities.
Cleavable linkers fall into two primary categories that allow for cleavage either through enzymatic digestion or exposure to pH extremes. (70) (71) (72) (73) (74) (75) (76) There is an ever growing list of linker chemistries with distinctive capabilities that are being tested in diverse ADC applications. (77) These desirable delivery characteristics subsequently make the drug and linker susceptible to premature degradation and cleavage during storage which limits the potential formulation compositions considerably when compared to that of formulation of a naked mAb. (75, 78) Depending upon the selected linker and the method of conjugation of the linker to the antibody, critical antibody characteristics that directly affect solubility, including surface charge and zetapotential, can be negatively impacted. For these reasons, drug, linker composition, and antibody target are all critical components specifically selected to address the unique demands of the intended therapeutic application and unfortunately result in significantly more complex formulation demands.
CURRENT ADC FORMULATION
As of the writing of this review there were only four FDA approved ADCs: brentuximab 
CONCLUSION
Despite there being only four currently approved ADC formulations we will continue to see growth in the area of next-generation modified antibodies for a variety of applications as there are currently >60 novel ADC formulations in clinical trials, >50% in Phase I. While the demand for high concentration ADCs has been thus far limited the rapidly increasing next-gen antibody conjugates that are on the horizon may cause formulation to become a large issue that will limit routes of administration or drive more site-specific antibody modification techniques to be utilized. Polyclonal antibodies and non-site-specific conjugation techniques result in very heterogeneous mixtures of antibodies which may make high concentration formulation more difficult to attain. Site-specific conjugation should likely allow for the most optimal formulation and highest concentration attainable due to less conjugation variability which directly reduces sample complexity. Successful high concentration antibody formulation will open the door to more accessible routes of administration such as intramuscular (IM) and subcutaneous (SC) injections which will expand the potential uses of antibodies and antibody conjugates in the treatment of diseases that currently remain out of reach due to the need for IV infusion. While the current chemotherapeutic and cytotoxic drug conjugates will continue to rise we should see an increase in alternate drug conjugates for cancer and non-cancer indications such as: peptides, diagnostic labels, immune-mediated disorders, cardiovascular/hemostasis, neurological, ophthalmic, infectious disease, metabolic disorders, respiratory diseases, immunotoxins, and immunocytokines, to list a few. (84, 85) With the increased diversity in antibody conjugates it is also likely that more novel excipients, and excipient combinations, will be submitted for FDA clearance as the variety and complexity of next-gen antibody conjugates continues to rise. 
